文献速递肾癌与肾肿瘤

纳武利尤单抗治疗转移性肾细胞癌的原发肾肿瘤反应:GETUG-AFU 26 NIVOREN 试验结果

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
PubMed 文献 · Eur Urol · 2021-06-05

在 GETUG-AFU 26 NIVOREN 2 期试验中,720 例转移性肾细胞癌患者中 111 例未行 upfront 减瘤性肾切除术并接受纳武利尤单抗治疗,其中 45% 和 49% 分别为 IMDC 中危和差危。该组客观缓解率为 16%(95%CI 10-25%),中位无进展生存期 2.7 个月(95%CI 2.5-4.0),中位总生存期 15.9 个月(95%CI 9.5-19.8);67 例可评估原发肾病灶中仅 4 例(6%)缩小超过 30%。结论提示未行 upfront 减瘤性肾切除术者基线特征不良,纳武利尤单抗对原发肿瘤活性有限。

要点

  • 未行 upfront 减瘤性肾切除术者多为 IMDC 中危(45%)和差危(49%)。
  • 纳武利尤单抗组客观缓解率为 16%(95%CI 10-25%)。
  • 可评估原发肾病灶中仅 6% 缩小超过 30%。

核心结论

  • 未行 upfront 减瘤性肾切除术患者基线特征不良,纳武利尤单抗对原发肾肿瘤活性有限。

研究设计与样本

  • GETUG-AFU-26 NIVOREN 2 期试验中 720 例转移性肾细胞癌患者,111 例未行 upfront 减瘤性肾切除术并接受纳武利尤单抗治疗。

主要发现

  • 111 例中 63% 为二线用药、37% 为三线或以上,客观缓解率 16%(95%CI 10-25%)。
  • 中位随访 24.5 个月(95%CI 21.6-27.1),中位无进展生存期 2.7 个月(95%CI 2.5-4.0),中位总生存期 15.9 个月(95%CI 9.5-19.8)。
  • 67 例可评估原发肾病灶中 4 例(6%)缩小超过 30%。

临床怎么用

  • 对未行 upfront 减瘤性肾切除术的转移性肾细胞癌患者,不应期待纳武利尤单抗对原发肾肿瘤有显著缩瘤效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary tumour response may impact therapeutic strategies in metastatic renal cell carcinoma (mRCC) but remains unknown in the era of immune checkpoint inhibitors. We aimed to describe the response of the primary tumour in patients who did not undergo upfront cytoreductive nephrectomy (uCN) and were treated with nivolumab in the GETUG-AFU-26 NIVOREN phase 2 trial. Primary tumour response was prospectively assessed, as well as the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Among 720 patients, 111 did not undergo uCN, mainly patients with intermediate (45%) and poor (49%) International mRCC Database Consortium (IMDC) risk. In the 111 patients, nivolumab was used in the second line for 63% of patients and the third line or more for 37%, with an ORR of 16% (95% confidence interval [CI] 1025%); with a median follow-up of 24.5 mo (95% CI 21.6-27.1), median PFS was 2.7 mo (95% CI 2.5-4.0) and median OS was 15.9 mo (95% CI 9.5-19.8). A total of 67 patients had an evaluable primary renal lesion, four of whom (6%) experienced shrinkage of more than 30%. Overall, patients who did not undergo uCN had adverse baseline characteristics and nivolumab activity against the primary tumour was limited. PATIENT SUMMARY: In this report, we observed that nivolumab was associated with a limited response of the primary tumour in previously treated patients with metastatic kidney cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Courcier J, Dalban C, Laguerre B, et al. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. Eur Urol. 2021. PMID: 34103181. doi:10.1016/j.eururo.2021.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。